These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 1546130)
1. Depression and senile dementia of the Alzheimer type: a role for moclobemide. Chan-Palay V Psychopharmacology (Berl); 1992; 106 Suppl():S137-9. PubMed ID: 1546130 [TBL] [Abstract][Full Text] [Related]
2. High urinary norepinephrine excretion in major depressive disorders: effects of a new type of MAO inhibitor (Moclobemide, RO 11-1163). Dajas F; Lista A; Barbeito L Acta Psychiatr Scand; 1984 Nov; 70(5):432-7. PubMed ID: 6516893 [TBL] [Abstract][Full Text] [Related]
3. Moclobemide for depression. Drug Ther Bull; 1994 Jan; 32(1):6-8. PubMed ID: 7635005 [TBL] [Abstract][Full Text] [Related]
4. Moclobemide and selegeline in the treatment of depression in Parkinson's disease. Steur EN; Ballering LA J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):547. PubMed ID: 9343144 [No Abstract] [Full Text] [Related]
5. Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression. A double blind, randomized study. Radat F; Berlin I; Spreux-Varoquaux O; Elatki S; Ferreri M; Puech AJ Psychopharmacology (Berl); 1996 Oct; 127(4):370-6. PubMed ID: 8923574 [TBL] [Abstract][Full Text] [Related]
6. Moclobemide and the reversible inhibitors of monoamine oxidase antidepressants. Priest RG Acta Psychiatr Scand Suppl; 1990; 360():39-41. PubMed ID: 2248065 [No Abstract] [Full Text] [Related]
7. A controlled double-blind trial of moclobemide and imipramine in the treatment of depression. Kok LP; Tsoi WF Singapore Med J; 1995 Feb; 36(1):38-40. PubMed ID: 7570133 [TBL] [Abstract][Full Text] [Related]
8. [Moclobemide (Aurorix), the first MAO-A-inhibitor: really something new?]. Nolen WA; Birkenhäger TK; Moleman P Ned Tijdschr Geneeskd; 1992 Aug; 136(31):1492-6. PubMed ID: 1495565 [No Abstract] [Full Text] [Related]
9. Depression in medical illness. Workshop report. Paykel E Int Clin Psychopharmacol; 1993 Jan; 7(3-4):205-7. PubMed ID: 8468445 [No Abstract] [Full Text] [Related]
10. The efficacy of reversible monoamine oxidase inhibitors in depressive illness. Roth M; Guelfi JD Can J Psychiatry; 1992 Sep; 37 Suppl 1():18-24. PubMed ID: 1394027 [TBL] [Abstract][Full Text] [Related]
11. [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge]. Volz HP; Gleiter CH; Möller HJ Nervenarzt; 1996 May; 67(5):339-47. PubMed ID: 9005342 [TBL] [Abstract][Full Text] [Related]
12. [Moclobemide in the treatment of depression--an overview]. Laux G Psychiatr Prax; 1989 Aug; 16 Suppl 1():37-40. PubMed ID: 2685855 [TBL] [Abstract][Full Text] [Related]
13. [Moclobemide]. Gleiter C; Volz HP Dtsch Med Wochenschr; 1995 Aug; 120(34-35):1175-6. PubMed ID: 7656852 [No Abstract] [Full Text] [Related]
14. RIMA: a safe concept in the treatment of depression with moclobemide. Amrein R; Hetzel W; Stabl M; Schmid-Burgk W Can J Psychiatry; 1992 Sep; 37 Suppl 1():7-11. PubMed ID: 1394030 [TBL] [Abstract][Full Text] [Related]
15. Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness. Fitton A; Faulds D; Goa KL Drugs; 1992 Apr; 43(4):561-96. PubMed ID: 1377119 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of moclobemide in different patient groups: a meta-analysis of studies. Angst J; Stabl M Psychopharmacology (Berl); 1992; 106 Suppl():S109-13. PubMed ID: 1347658 [TBL] [Abstract][Full Text] [Related]